Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724984 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00724984 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 55 participants.
The verdict
NCT00724984, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.
Interventions
- DRUG PCI-24781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724984
The ClinicalTrials.gov registry entry for NCT00724984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCI-24781 is the first listed.
NCT00724984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724984 about?
NCT00724984 is a clinical study titled "Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma". The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 di...
What is the current status of trial NCT00724984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00724984?
The interventions under investigation include: PCI-24781 (DRUG).
Who is sponsoring clinical trial NCT00724984?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.